Theralase at forefront of cold laser therapy: targets cellular biology to relieve pain, excise cancer
It’s a rare treat for this writer to meet a CEO who can explain the molecular rudiments of his products. Such is the case of Roger Dumoulin-White, CEO of Theralase Technologies Inc. (‘Theralase’ | TSXV: TLT | OTCBB: TLTFF) is a Canadian company that provides novel pain and cancer treatment options using the power of laser light and Photo Dynamic Compounds (PDCs). These are drugs which, when exposed to very specific types of light, become active in destroying cancer cells.
In a field with over a thousand kinds of lasers in both research and commercial applications, suffice to know that not all lasers are equal: some cut through metals at tremendous temperatures whereas some gently painlessly penetrate flesh to heal pain with no noticeable temperatures.
Theralase targets two treatment modalities using cold lasers: pain treatment and cancer therapy.
Theralase’s 1200 commercial lasers already in commercial use penetrate skin and muscles to heal. I call this treatment laser acupuncture but in the hallways of academia the technique is called Low Level Laser Therapy (LLLT) which is the use of therapeutic (or cold) laser light to provide relief from pain, eliminate inflammation (swelling) or to repair damaged tissues.
LLLT is entirely non-invasive and has a wide range of applications, from neural muscular skeletal conditions to wound healing to acupuncture treatments in both human and veterinary applications. Rather than destroying tissue, as with surgical (or hot) lasers, LLLT uses low intensity laser light energy to stimulate cells through a number of known cellular pathways in order to encourage tissue healing.
I’ve had low-level laser therapy (LLLT) from my chiropractor for over fifteen years to fix back and neck pains from logging and Crossfit injuries. The therapist applies a laser probe to the skin above the area to treat for a period time.
Get our daily investorintel update
Like any new treatment modality, LLLT is scrutinized by mainstream medicine. However, Theralase’s approach is to understand the impact of laser therapy on specific enzymes in specific organelles, a consolidated body of knowledge that the company is acquiring through systematic investigations that remind me of graduate school.
Some of the questions under investigation are the ideal location of treatment (specifically whether LLLT is more appropriately used over nerves versus joints), dose, wavelength, timing, pulsing and duration. The effects of LLLT appear to be limited to specific sets of wavelengths of laser, and administering LLLT below the dose range does not appear to be effective. But to date, LLLT has been shown to be effective in relieving short-term pain for rheumatoid arthritis, osteoarthritis, acute and chronic neck pain, tendinopathy, and shows promises for chronic joint disorders.
While Theralase is mainstreaming LLLT its current cancer research may propel it to the front of molecular medicine. Cancer treatment can also effected through LLLT at specific wavelengths through the excitement of photodynamic compounds that are benign under normal conditions but become cytotoxic when activated by specific wavelengths. Theralase has proven this approach in mouse studies as well as using human cancer cells in the laboratory and is working toward clinical trials. Further yet, two of the company’s photodynamic compounds were proven to destroy 2 types of bacteria (Staphylococcus aureus (s. aureus) and Methicillin Resistant Staphylococcus aureus (MRSA)) in low oxygen atmospheres. The results are considered pivotal because the Theralase PDCs efficacy has been validated in both normal and low oxygen environments.
Dr. Luc C. Duchesne is a Speaker and Author with a PhD in Biochemistry. With three decades of scientific and business experience, he has published ... <Read more about Dr. Luc Duchesne>